Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
By R. Nanda, L. Chow, C. Dees, R. Berger, Shilpa Gupta, R. Geva, L. Pusztai, K. Pathiraja, G. Aktan, Jonathan D. Cheng and 2 more. Journal of Clinical Oncology, 2016
1,336 citations recorded by the source corpus.
Subfields: Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/00be325f375a0f0a51583fe0dc43d7098e8ff137
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Oncology
Citations in the corpus
- Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study (2017, background): “5 and 13% reported for patients with PD-L1+ TNBC treated with pembrolizumab and atezolizumab, respectively [17, 19].”
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study (2019, neutral): “(%) [95% CI] 5 (24) [8-47] 10 (11) [5-19] 0 [0-17] 15 (16) [10-26]”
- Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016, background): “reporting 27 patients with PD-L1 positive metastatic TN breast cancer treated with pembrolizumab as a monotherapy showed an overall response rate of 19 % with one complete response and four partial responses as well as 26 % patients with stable disease [32].”